Building an Equitable Foundation for Regenerative Medicine

Although breakthrough research in regenerative medicine holds immense promise for saving lives, experts argue that the field must establish a more robust and inclusive foundation to truly thrive. Over the last thirty years, rapid advancements have been driven by innovations such as cell therapy—where specific cells are introduced into patients to combat disease—and tissue engineering, which employs various techniques to regenerate or repair damaged human tissues.

A key driver of this progress is the development of induced pluripotent stem cells (iPSCs), which possess the ability to differentiate into any cell type within the body. These versatile cells are currently being utilized to design potential therapies for serious conditions, including heart failure, Parkinson’s disease, and autoimmune disorders. Furthermore, recent clinical trials involving stem-cell transplants aimed at replacing insulin-producing cells in patients with type 1 diabetes have shown signs of success.

Despite these scientific achievements, there are growing concerns regarding the diversity of the research community. A lack of female researchers and participants in regenerative-medicine studies is identified as a significant barrier, potentially holding back the field’s overall advancement. To fully realize its potential, the industry must address these gaps and ensure a more equitable approach to both the workforce and clinical trial populations.

This perspective is part of the Nature Index 2026 Regenerative Medicine supplement, which also explores other critical dimensions of the field, including the rising competition among researchers and the scaling of cellular therapy infrastructure.